RAGE: a novel target for drug intervention in diabetic vascular disease

Area of Science:

• Biochemistry
• Molecular Biology
• Pathology

Background:

• High glucose levels in diabetes lead to the formation of advanced glycation end products (AGEs).
• AGEs modify proteins and DNA, causing cellular dysfunction and promoting vascular disease.
• The receptor for advanced glycation end products (RAGE) is a key mediator in AGE-induced cellular responses.

Purpose of the Study:

• To investigate the role of the AGE/RAGE pathway in the pathogenesis of vascular complications.
• To evaluate the therapeutic potential of blocking AGE-RAGE interactions in preventing vascular disease.

Main Methods:

• Studied the formation of AGEs and their interaction with RAGE in cellular models.
• Utilized small animal models to assess the impact of blocking AGE-RAGE interactions on microvascular and macrovascular disease.
• Examined the influence of RAGE allelic variants on disease outcomes.

Main Results:

• Accumulation of AGEs and RAGE, along with other RAGE ligands like S100/calgranulins, is characteristic of disease pathogenesis.
• Blocking AGE-RAGE interactions at the protein or genetic level inhibited the development of nephropathy, atherosclerosis, and restenosis in animal models.
• Identified RAGE allelic variants that modulate protein function and gene expression, potentially impacting disease severity.

Conclusions:

• The AGE/RAGE axis plays a critical role in the development of vascular disease.
• Targeting the AGE-RAGE interaction presents a promising therapeutic strategy for preventing vascular complications in both diabetic and non-diabetic individuals.
• RAGE is a viable target for drug development aimed at mitigating vascular disease.